Many laboratories have attempted to develop an in vitro or in vivo test to characterize the sensitivity or resistance of human tumours to specific drugs for subsequent clinical use (for review see Mattern & Volm, 1982 ). It appears that in spite of apparent improvements in the methods, the information provided by these systems remains the same: Clinical correlations of results have shown that most tests can determine which anticancer drugs will not be clinically useful, but none satisfactorily predict which drugs will be most effective (Salmon et al, 1978; Volm et al., 1979) . Thus, although some procedures have achieved clinical importance in a few centers (e.g. Group for Sensitivity Testing of Tumours, 1981) , no single test system has acquired widespread clinical acceptance. It is therefore not surprising that a general disillusionment has developed in this area of research.
However, perhaps the wrong question has been asked. Instead of predicting which particular drugs may or may not be effective in any individual patient it may be that the more important question to address is: 'Which patients would benefit from any course of chemotherapy?' Frequently, resistant cells possess a cross-resistance to a wide range of compounds which have no obvious structural or functional similarities (e.g. alkaloids, anthracyclines and antibiotics). This phenomenon has been designated as pleiotropic or multidrug resistance (Bech-Hansen et al., 1976) . With this in mind we used in the present prospective study a simple test in which a tumour cell suspension is prepared from the fresh surgical specimen, treated with adriamycin and the uptake of radioactive nucleic acid precursors is determined (Volm et al., 1979; Volm, 1984 daily, repeated every 6 weeks for 4-6 cycles. (C) cisplatinum (120 mgm 2 X 1), vindesine (3mgm-2 X 1) weekly for 6 weeks, then every 2 weeks for 6 months. Follow-up data were obtained through hospital charts and correspondence with the patients' referring physicians. Patients surviving less than 4 weeks after surgery were excluded from the study (3 pts). No patients were lost to follow-up.
Tumours of all patients were analyzed by the in vitro test. The short term test has been described earlier (Volm et al., 1979; Volm, 1984) . Briefly, the suspensions are incubated with adriamycin (concentration, 0.1-100pgml-1) in a water bath for 3h. Subsequently, 3H-uridine is added during the last hour of incubation. Aliquots of the cell suspensions are pipetted onto filter discs, the acid-soluble radioactivity is extracted, and the incorporated activity measured by scintillation counting. Uptake values for the individual concentrations are expressed as percentages of controls. Tumours were defined as being sensitive or resistant depending on whether uridine uptake was inhibited by more or less than 35%, respectively (concentration of adriamycin: 10gml-1). This threshold was based on earlier studies (Volm et al., 1979 ; Group for Sensitivity Testing of Tumours, 1981) .
The method for analysis of survival was the statistical failure time model with censored data according to Kaplan and Meier (1958) . For comparison of the functions of different populations the log-rank test and rank-sum test were used (Gehan, 1965; Cox, 1972) . Both statistical methods are integrated in a program package of the German Cancer Institute, Heidelberg (Edler et al., 1980) .
Of the 32 patients in this study with previously untreated adenocarcinoma of the lung in stage III, 14 were treated with surgery alone (group S) and 18 were treated with surgery plus chemotherapy (group CT). An analysis of the survival times reveals that the survival curves are not different between the S and CT groups (log-rank p=0.63, rank-sum P = 0.39, Figure l a realize that while the numbers of patients are small, the survival times of patients who were treated with surgery alone and divided according to the test results were not different (log-rank P=0.14, rank-sum, P=0.24, Figure lc --S = surgery alone, CT = surgery plus chemotherapy, sens = sensitive, res = resistant, L=lobectomy, P = pneumonectomy, R = resection, A, B, C = chemotherapy protocols (see text); amean + s.d.
